Targeting amylin is hoped to preserve muscle ... But the Carmot drug is engineered with “biased signaling” that de-emphasizes pathways that could diminish tolerability and efficacy.

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.

The Artisan International Small-Mid Fund portfolio outperformed the MSCI ACWI ex USA SMID Index in Q4 of 2024. Click here to ...

AbbVie (ABBV) has agreed to license a weight-loss drug currently in development from Danish biotech firm Gubra for up to about $2.2 billion, signaling ... of the hormone amylin, which has been ...

AbbVie (ABBV) has agreed to license a weight-loss drug currently in development from Danish biotech firm Gubra for up to about $2.2 billion, signaling its entry in ... acts as an analog of the hormone ...

The remaining deals split across other possible mechanisms such as activin and myostatin, GIP, dual GIP/GLP-1 and amylin. “Despite Novo Nordisk ... demand for improved GLP-1 safety and tolerability, ...

The outlay, plus up to $3.6 billion in milestones, has secured Roche the right to codevelop and co-commercialize Zealand Pharma’s long-acting amylin analog petrelintide. Excitement about the ...

In what it says is the biggest obesity deal to date, Zealand Pharma A/S has signed up Roche AG to a potential $5.3 billion global collaboration and license agreement to develop petrelintide, an amylin ...

Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...